Ligand Pharmaceuticals Inc. (LGND)

104.00
NASDAQ : Health Technology
Prev Close 104.69
Day Low/High 103.09 / 107.67
52 Wk Low/High 84.45 / 278.62
Avg Volume 427.20K
Exchange NASDAQ
Shares Outstanding 19.01M
Market Cap 1.99B
EPS 6.80
P/E Ratio 2.97
Div & Yield N.A. (N.A)
LGND: Insiders Vs. Shorts

LGND: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Ligand Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 23.29 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ligand To Participate In The H. C. Wainwright 21st Annual Global Investment Conference

Ligand To Participate In The H. C. Wainwright 21st Annual Global Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the H.

Ligand Partner CASI Pharmaceuticals Launches EVOMELA® In China

Ligand Partner CASI Pharmaceuticals Launches EVOMELA® In China

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Ligand Reports Second Quarter 2019 Financial Results

Ligand Reports Second Quarter 2019 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2019, and provided an operating forecast and program updates.

Ligand Acquires Ab Initio Biotherapeutics, An Antigen-Discovery Company

Ligand Acquires Ab Initio Biotherapeutics, An Antigen-Discovery Company

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash.

Lemelson Capital Management Announces 1H, 2019 Financial Results For The Amvona Fund, LP

Lemelson Capital Management Announces 1H, 2019 Financial Results For The Amvona Fund, LP

Short position in Ligand pharmaceuticals, long position in Geospace Technologies, contribute to 70.27[1] percent net return in 1H, 2019

Ligand To Report Second Quarter 2019 Results On July 30th

Ligand To Report Second Quarter 2019 Results On July 30th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2019 financial results on July 30, 2019.

Ligand Announces Positive Top Line Results From Phase 1 Clinical Trial Of Captisol-enabled Iohexol

Ligand Announces Positive Top Line Results From Phase 1 Clinical Trial Of Captisol-enabled Iohexol

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program.

Ligand And SQ Innovation Enter Into Exclusive Worldwide Captisol® License And Supply Agreements For High-Concentration Furosemide Formulation

Ligand And SQ Innovation Enter Into Exclusive Worldwide Captisol® License And Supply Agreements For High-Concentration Furosemide Formulation

SQ Innovation will use Ligand's Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure.

Ligand And SQ Innovation Enter Into Exclusive Worldwide Captisol® License And Supply Agreements For High-Concentration Furosemide Formulation

Ligand And SQ Innovation Enter Into Exclusive Worldwide Captisol® License And Supply Agreements For High-Concentration Furosemide Formulation

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and SQ Innovation AG today announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand's Captisol ® technology in the formulation of...

ZULRESSO™ (brexanolone) CIV, A Product For Treating Postpartum Depression Using Ligand's Captisol® In Its Formulation, Launched By Sage Therapeutics

ZULRESSO™ (brexanolone) CIV, A Product For Treating Postpartum Depression Using Ligand's Captisol® In Its Formulation, Launched By Sage Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.

LGND: Insiders Vs. Shorts

LGND: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Ligand Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 23.29 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ligand Subsidiary Vernalis And PhoreMost Limited Announce Drug Discovery Collaboration For Novel Oncology Target

Ligand Subsidiary Vernalis And PhoreMost Limited Announce Drug Discovery Collaboration For Novel Oncology Target

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand's subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.

Ligand Licenses VER250840 To Cumulus Oncology

Ligand Licenses VER250840 To Cumulus Oncology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor...

Ligand Acquires Milestone And Royalty Rights To SB206 From Novan, Inc.

Ligand Acquires Milestone And Royalty Rights To SB206 From Novan, Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc.

Ligand Reports First Quarter 2019 Financial Results

Ligand Reports First Quarter 2019 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2019 and provided an operating forecast and program updates.

Ligand Completes Enrollment Of Phase 1 Clinical Trial Of Captisol-enabled Iohexol

Ligand Completes Enrollment Of Phase 1 Clinical Trial Of Captisol-enabled Iohexol

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion of enrollment of the Company's Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program.

Ligand To Report First Quarter 2019 Results On May 2nd

Ligand To Report First Quarter 2019 Results On May 2nd

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2019 financial results on May 2, 2019.

Ligand To Receive Milestone And Royalties As Result Of FDA Approval Of Sage Therapeutics' ZULRESSO™ (brexanolone) Injection

Ligand To Receive Milestone And Royalties As Result Of FDA Approval Of Sage Therapeutics' ZULRESSO™ (brexanolone) Injection

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it will receive a $3 million milestone payment as a result of the U.

LGND: Insiders Vs. Shorts

LGND: Insiders Vs. Shorts

The most recent short interest data was recently released for the 02/28/2019 settlement date, and Ligand Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 17.35 "days to cover" versus the median component at 4.57. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Ligand To Participate In Four Upcoming Investor Conferences

Ligand To Participate In Four Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: Barclays Global Healthcare Conference in Miami.

Ligand Provides Highlights From Today's Analyst Day Event

Ligand Provides Highlights From Today's Analyst Day Event

At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business and financial growth outlook.

Notable Wednesday Option Activity: LGND, TLYS, MRNS

Notable Wednesday Option Activity: LGND, TLYS, MRNS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ligand Pharmaceuticals Inc , where a total of 2,471 contracts have traded so far, representing approximately 247,100 underlying shares. That amounts to about 50.7% of LGND's average daily trading volume over the past month of 487,390 shares.

Ligand Sells Promacta Assets And Royalty For $827 Million

Ligand Sells Promacta Assets And Royalty For $827 Million

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand's Promacta ®-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for...

Short-Selling Is Really Hard. Just Ask Citron Research

Short-Selling Is Really Hard. Just Ask Citron Research

Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.

Reminder: Ligand To Host Analyst Day On March 12th In New York City

Reminder: Ligand To Host Analyst Day On March 12th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.

Ligand Reports Fourth Quarter And Full Year 2018 Financial Results

Ligand Reports Fourth Quarter And Full Year 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018, and provided an operating forecast and program updates.

Ligand Announces OmniAb® Partnership With Genagon Therapeutics

Ligand Announces OmniAb® Partnership With Genagon Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.

Ligand Announces Investment In Dianomi Therapeutics

Ligand Announces Investment In Dianomi Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces closing an investment in Dianomi Therapeutics, Inc.

TheStreet Quant Rating: C (Hold)